AstraZeneca
Rating
Updated: Aug 26, 2026Why Price Moved
Shares are trading higher after AstraZeneca and Da...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufa...
Latest News
6 hours ago · zacks.com
AZN vs. MRK: Comparing Keytruda, Pipelines and Growth StrategiesAZN and MRK bring distinct oncology strengths, growth plans, pipeline opportunities and patent-related challenges to the table.
3 days ago · zacks.com
FDA Grants Priority Review to AZN's Filing for Rare Bone Disease DrugAstraZeneca wins FDA priority review for efzimfotase alfa, potentially expanding its HPP treatment opportunity with less frequent dosing.
3 days ago · zacks.com
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.
4 days ago · reuters.com
AstraZeneca-Daiichi breast cancer drug cleared for NHS use in EnglandAstraZeneca and Daiichi Sankyo said on Thursday their breast cancer treatment Enhertu has been approved for use in England's state-run healthcare system, expanding access to a drug that has been available in Scotland since 2023.
5 days ago · gurufocus.com
AstraZeneca Shares Rise as J.P. Morgan Stays OverweightAstraZeneca plc (AZN) rose 2.16% intraday after J.P. Morgan reiterated an Overweight rating, pointing to six Phase III readouts due in 2027 that together carry
5 days ago · zacks.com
Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views?The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
6 days ago · benzinga.com
AstraZeneca, Leidos, Expeditors International And More On CNBC's ‘Final Trades'On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, picked AstraZeneca PLC (NYSE:AZN),
6 days ago · zacks.com
Why the Market Dipped But Astrazeneca (AZN) Gained TodayIn the latest trading session, Astrazeneca (AZN) closed at $163.78, marking a +2.25% move from the previous day.
7 days ago · zacks.com
AZN's Etcamah Fails Late-Stage Study for First-line Breast CancerAstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.
8 days ago · wsj.com
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage TrialThe Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.
Add to Watchlist
Select watchlists to add or remove AZN